Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the c
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
03:26pm, Thursday, 26'th Mar 2026
DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
06:55am, Thursday, 26'th Mar 2026
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
02:08pm, Wednesday, 25'th Mar 2026
Denali Therapeutics won FDA approval Wednesday for the first new drug in 20 years to treat a rare genetic disease.
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
11:50am, Wednesday, 25'th Mar 2026
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts
01:02am, Saturday, 21'st Mar 2026
Denali Therapeutics (NASDAQ: DNLI) founder and CEO Ryan Watts said 2026 is shaping up to be a pivotal year for the company as it approaches a potential first product approval and advances multiple tra
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
08:22pm, Friday, 20'th Mar 2026
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI
04:35am, Monday, 16'th Mar 2026
Cantor Fitzgerald L. P. acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) during the undefined quarter, according to its most recent disclosure with the SEC. The institution
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
12:35pm, Wednesday, 11'th Mar 2026
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:55pm, Friday, 06'th Mar 2026
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
FDA reversals leave investors worrying about the fates of other experimental drugs
11:33am, Friday, 06'th Mar 2026
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
10:06am, Friday, 27'th Feb 2026
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
04:01pm, Thursday, 26'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, an
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
08:30am, Thursday, 19'th Feb 2026
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical com
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI
04:22am, Thursday, 19'th Feb 2026
Aberdeen Group plc grew its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 23.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities
